These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1539 related items for PubMed ID: 15936549

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phase II dose escalation study of image-guided adaptive radiotherapy for prostate cancer: use of dose-volume constraints to achieve rectal isotoxicity.
    Vargas C, Yan D, Kestin LL, Krauss D, Lockman DM, Brabbins DS, Martinez AA.
    Int J Radiat Oncol Biol Phys; 2005 Sep 01; 63(1):141-9. PubMed ID: 16111582
    [Abstract] [Full Text] [Related]

  • 5. A dose-escalation trial with the adaptive radiotherapy process as a delivery system in localized prostate cancer: analysis of chronic toxicity.
    Brabbins D, Martinez A, Yan D, Lockman D, Wallace M, Gustafson G, Chen P, Vicini F, Wong J.
    Int J Radiat Oncol Biol Phys; 2005 Feb 01; 61(2):400-8. PubMed ID: 15667959
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Short-course, intensity-modulated radiotherapy for localized prostate cancer.
    Kupelian PA, Willoughby TR.
    Cancer J; 2001 Feb 01; 7(5):421-6. PubMed ID: 11693901
    [Abstract] [Full Text] [Related]

  • 10. High dose radiation delivered by intensity modulated conformal radiotherapy improves the outcome of localized prostate cancer.
    Zelefsky MJ, Fuks Z, Hunt M, Lee HJ, Lombardi D, Ling CC, Reuter VE, Venkatraman ES, Leibel SA.
    J Urol; 2001 Sep 01; 166(3):876-81. PubMed ID: 11490237
    [Abstract] [Full Text] [Related]

  • 11. The feasibility of dose escalation with three-dimensional conformal radiotherapy in patients with prostatic carcinoma.
    Zelefsky MJ, Leibel SA, Kutcher GJ, Kelson S, Ling CC, Fuks Z.
    Cancer J Sci Am; 1995 Sep 01; 1(2):142-50. PubMed ID: 9166467
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Pilot study of conformal intensity modulated radiation therapy for localized prostate cancer.
    Aillères N, Azria D, Thézenas S, Barbier N, Fenoglietto P, Delard R, Hay MH, Dubois JB.
    Cancer Radiother; 2004 Apr 01; 8(2):59-69. PubMed ID: 15063872
    [Abstract] [Full Text] [Related]

  • 15. The GETUG 70 Gy vs. 80 Gy randomized trial for localized prostate cancer: feasibility and acute toxicity.
    Beckendorf V, Guérif S, Le Prisé E, Cosset JM, Lefloch O, Chauvet B, Salem N, Chapet O, Bourdin S, Bachaud JM, Maingon P, Lagrange JL, Malissard L, Simon JM, Pommier P, Hay MH, Dubray B, Luporsi E, Bey P.
    Int J Radiat Oncol Biol Phys; 2004 Nov 15; 60(4):1056-65. PubMed ID: 15519775
    [Abstract] [Full Text] [Related]

  • 16. Phase I-II study of hypofractionated simultaneous integrated boost with tomotherapy for prostate cancer.
    Di Muzio N, Fiorino C, Cozzarini C, Alongi F, Broggi S, Mangili P, Guazzoni G, Valdagni R, Calandrino R, Fazio F.
    Int J Radiat Oncol Biol Phys; 2009 Jun 01; 74(2):392-8. PubMed ID: 19056184
    [Abstract] [Full Text] [Related]

  • 17. Comparison of late rectal toxicity from conventional versus three-dimensional conformal radiotherapy for prostate cancer: analysis of clinical and dosimetric factors.
    Lee CM, Lee RJ, Handrahan DL, Sause WT.
    Urology; 2005 Jan 01; 65(1):114-9. PubMed ID: 15667875
    [Abstract] [Full Text] [Related]

  • 18. Hypofractionated intensity-modulated arc therapy for lymph node metastasized prostate cancer.
    Fonteyne V, De Gersem W, De Neve W, Jacobs F, Lumen N, Vandecasteele K, Villeirs G, De Meerleer G.
    Int J Radiat Oncol Biol Phys; 2009 Nov 15; 75(4):1013-20. PubMed ID: 19386427
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Interim report of toxicity from 3D conformal radiation therapy (3D-CRT) for prostate cancer on 3DOG/RTOG 9406, level III (79.2 Gy).
    Ryu JK, Winter K, Michalski JM, Purdy JA, Markoe AM, Earle JD, Perez CA, Roach M, Sandler HM, Pollack A, Cox JD.
    Int J Radiat Oncol Biol Phys; 2002 Nov 15; 54(4):1036-46. PubMed ID: 12419429
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 77.